Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening.
Rebecca L ThomasThomas G WinfieldMatthew PrettyjohnsFrank D DunstanWai-Yee CheungPhilippa M AndersonRajesh PeterStephen D LuzioDavid R OwensPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2020)
Base case and sensitivity analyses indicate biennial screening to be cost-effective for T2DM irrespective of HbA1c and duration of diabetes. However, the uncertainty around the DCER indicates that annual screening should be maintained for those with T1DM especially when the HbA1c exceeds 80 mmol/mol (9.5%) and duration of diabetes is greater than 12 years.